Effects of non‐steroidal anti‐inflammatory drug treatments on cognitive decline vary by phase of pre‐clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti‐inflammatory Prevention Trial
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Objective: We examined the effects of non‐steroidal anti‐inflammatory drugs on cognitive decline as a function of phase of pre‐clinical Alzheimer disease. Methods: Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre‐clinical Alzheimer disease. We fit growth mixture models of Modified Mini‐Mental State (3MS) Examination trajectories with data from 2388 participants in the Alzheimer's Disease Anti‐inflammatory Prevention Trial and included class‐specific effects of naproxen and celecoxib. Results: We identified three classes: “no decline”, “slow decline”, and “fast decline”, and examined the effects of celecoxib and naproxen on linear slope and rate of change by class. Inclusion of quadratic terms improved fit of the model (−2 log likelihood difference: 369.23;p < 0.001) but resulted in reversal of effects over time. Over 4 years, participants in the slow‐decline class on placebo typically lost 6.6 3MS points, whereas those on naproxen lost 3.1 points (p‐value for difference: 0.19). Participants in the fast‐decline class on placebo typically lost 11.2 points, but those on celecoxib first declined and then gained points (p‐value for difference from placebo: 0.04), whereas those on naproxen showed a typical decline of 24.9 points (p‐value for difference from placebo: <0.0001). Conclusions: Our results appeared statistically robust but provided some unexpected contrasts in effects of different treatments at different times. Naproxen may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners. Celecoxib appeared to have similar effects at first but then attenuated change in fast decliners. Copyright © 2011 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nylund, K. L., Asparouhov, T., & Muthén, B. O. (2007) · Structural Equation Modeling: A Multidisciplinary Journal · doi:10.1080/10705510701575396 · Cited by 11,415
Self-citationFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366 · cited 1×
“Several prospective studies of asymptomatic individuals with higher genetic risk have documented subtle memory declines, which predicted conversion to MCI and correlated with cerebral glucose metabolism (Reiman et al., 1996; Casellie et al., 2008).”
BackgroundWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Prodromal Alzheimer's disease: successive emergence of the clinical symptoms
Amieva, H., Le Goff, M., Millet, X., Orgogozo, J. M., Pérès, K., Barberger‐Gateau, P., Jacqmin‐Gadda, H., & Dartigues, J. F. (2008) · Annals of Neurology · doi:10.1002/ana.21509 · Cited by 737
Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis
Bäckman, L., Jones, S., Berger, A.-K., Laukka, E. J., & Small, B. J. (2005) · Neuropsychology · doi:10.1037/0894-4105.19.4.520 · Cited by 735
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535 · cited 2×
“More recent studies, including the Cardiovascular Health Study (CHS) and a case–control analysis of 246,199 US veterans, also report reduced AD risk among NSAID users, although a 12‐year cohort study of 1019 older Catholic clergy found no association (Arvanitakis et al., 2008; Szekely et al., 2008a; Vlad et al., 2008).”
BackgroundResultA Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment
on behalf of the Rofecoxib Protocol 078 study group, Thal, L. J., Ferris, S. H., Kirby, L., Block, G. A., Lines, C. R., Yuen, E., Assaid, C., Nessly, M. L., Norman, B. A., et al. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300690 · Cited by 402 · cited 1×
“A large RCT of rofecoxibMCI showed increased AD hazard (Thal et al., 2005).”
BackgroundNaproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354 · cited 3×
“Study methods have been previously reported in detail (ADAPT Research Group et al., 2007).”
BackgroundMethodInfluentialNeuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease
Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., & Maccioni, R. B. (2008) · Archives of Medical Research · doi:10.1016/j.arcmed.2007.10.001 · Cited by 351 · cited 1×
“The cytokine interleukin‐3 (IL‐3) has been shown to inhibit Aβ(1–42)‐mediated neuronal death (Rojo et al., 2008), and compared with normal older controls, those with mild AD have lower secretion of IL‐3 by mononuclear cells (Huberman et al., 1994).”
BackgroundSmall, B. J., Fratiglioni, L., Viitanen, M., Winblad, B., & Bäckman, L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.839 · Cited by 329
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204
Self-citationRole of microglia in senile plaque formation
Mackenzie, I. R. A., Hao, C., & Munoz, D. G. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00092-s · Cited by 183
NSAIDs and incident Alzheimer’s disease. The Rotterdam study
In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00096-7 · Cited by 145
Microglial activation in early stages of amyloid β protein deposition
Sasaki, A., Yamaguchi, H., Ogawa, A., Sugihara, S., & Nakazato, Y. (1997) · Acta Neuropathologica · doi:10.1007/s004010050713 · Cited by 132 · cited 1×
“In autopsy studies of normal older individuals,microglia were associated with neuritic but not diffuse plaques (Mackenzie et al., 1995; Sasaki et al., 1997).”
BackgroundSzekely, C. A., Green, R. C., Breitner, J. C. S., Østbye, T., Beiser, A. S., Corrada, M. M., Dodge, H. H., Ganguli, M., Kawas, C. H., Kuller, L. H., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000313933.17796.f6 · Cited by 121 · cited 3×
“In the CHS, reduced risk of AD in NSAID users was only significant in the younger group (Szekely et al., 2008b).”
BackgroundSelf-citationEducation and the cognitive decline associated with MRI-defined brain infarct
Elkins, J. S., Longstreth, W. T., Manolio, T. A., Newman, A. B., Bhadelia, R. A., & Johnston, S. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228246.89109.98 · Cited by 108 · cited 1×
“For parity with other ADAPT analyses, we used education‐adjusted 3MS scores in all analyses (Elkins et al., 2006; ADAPT Research Group, 2008).”
MethodFripp, J., Bourgeat, P., Acosta, O., Raniga, P., Modat, M., Pike, K. E., Jones, G., O'Keefe, G., Masters, C. L., Ames, D., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.07.053 · Cited by 80 · cited 2×
“…with 11C‐PET‐PiB confirming the presence of amyloid in the brains of non‐impaired older individuals, and magnetic resonance imaging studies showing brain atrophy in cognitively normal subjects (Braak and Braak, 1997; Aizenstein et al., 2008; Fripp et al., 2008; Fennema‐Notestine et al., 2009).”
BackgroundAisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Cited by
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Morales, I., Guzmán-MartÃnez, L., Cerda-Troncoso, C., FarÃas, G. A., & Maccioni, R. B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00112 · Cited by 490
“Conversely, Celecoxib (another NSAID) appears to have similar effects, but attenuated changes in fast decliners (Leoutsakos et al., 2012).”
BackgroundThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467
The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease
Minter, M. R., Taylor, J. M., & Crack, P. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13411 · Cited by 451
Santos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
“Low-dose ed as an antidary CVD Mixed literature, suggesting that NSAIDs may confer modest protective effects [10,11].”
Background
Metadata
- Authors
- Leoutsakos, J. S., Muthen, B. O., Breitner, J. C. S., & Lyketsos, C. G.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2011-05-10
- Volume
- 27
- Issue
- 4
- Pages
- 364-374
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W2117901796
- Cited by
- 104
- References
- 20
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.